Literature DB >> 8015089

Cell type specific expression of steroid 5 alpha-reductase 2.

R I Silver1, E L Wiley, A E Thigpen, J M Guileyardo, J D McConnell, D W Russell.   

Abstract

Isozymes of steroid 5 alpha-reductase (5 alpha-reductase) have crucial roles in androgen physiology by synthesizing the potent hormone dihydrotestosterone. The expression pattern of the 5 alpha-reductase type 2 isozyme was determined in genital and extragenital tissues by developing an immunohistochemical assay using formalin-fixed tissue and affinity purified polyclonal antibodies that specifically recognize this isozyme. Expression was detected in basal epithelial and stromal cells of the normal prostate but not in luminal epithelial cells. Stromal cells of the seminal vesicle also expressed the type 2 isozyme. In contrast, staining was detected in epithelial cells of the epididymis but not in the surrounding stroma. Myofibroblasts in foreskin samples of normal and hypospadiac individuals expressed antigen and were distributed in bands throughout the prepuce, suggesting a clonal origin. In most cells the type 2 isozyme exhibited a perinuclear subcellular distribution. However, in liver hepatocytes the protein was distributed throughout the intracellular membrane compartment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8015089     DOI: 10.1016/s0022-5347(17)32758-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Regional distribution of 5α-reductase type 2 in the adult rat brain: an immunohistochemical analysis.

Authors:  M Paola Castelli; Alberto Casti; Angelo Casu; Roberto Frau; Marco Bortolato; Saturnino Spiga; Maria Grazia Ennas
Journal:  Psychoneuroendocrinology       Date:  2012-07-08       Impact factor: 4.905

3.  Finasteride and prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2004

4.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 5.  Endocrine and adrenergic pharmacological intervention in diseases of the prostate.

Authors:  A Rane
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 6.  Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

Review 7.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

8.  Long-Term Experience With 5-alpha-Reductase Inhibitors.

Authors:  E Darracott Vaughan
Journal:  Rev Urol       Date:  2003

9.  Long-Term Experience with 5-alpha-Reductase Inhibitors.

Authors:  E Darracott Vaughan
Journal:  Rev Urol       Date:  2003

10.  5α-Reductase Isozymes in the Prostate.

Authors:  Yuan-Shan Zhu; Guang-Huan Sun
Journal:  J Med Sci       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.